Lexicon Genetics gets U.K. approval to test small-molecule drug

08/1/2006 | Houston Chronicle (tiered subscription model)

Lexicon Genetics has the green light from British authorities to begin the first human trial of its drug to treat cognitive disorders such as Alzheimer's disease. The Texas firm currently is working with 300,000 mice and embryonic stem cells to block genes that may be associated with human diseases, and the upcoming trials will mark the company's entrance into the independent development of drugs.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA